SCYNEXIS, Inc. (SCYX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.11. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: SCYX trades at a trailing Price-to-Earnings (P/E) of -5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.15.
Financials: revenue is $21M, +1001.8%/yr average growth. Net income is $9M (loss), growing at +44.8%/yr. Net profit margin is -41.8% (negative). Gross margin is 100% (+12.3 pp trend).
Balance sheet: total debt is $2M against $49M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 7.04 (strong liquidity). Debt-to-assets is 3.7%. Total assets: $59M.
Analyst outlook: 13 / 14 analysts rate SCYX as buy (93%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
